Bank Of Montreal MicroSectors U.S. Big Oil 3 Leveraged ETNs due February 17, 2045 (ARCA: NRGU)

Ultime notizie per Bank Of Montreal MicroSectors U.S. Big Oil 3 Leveraged ETNs due February 17, 2045 (ARCA:NRGU)

The notes are senior unsecured medium-term notes issued by Bank of Montreal with a return linked to a three times leveraged participation in the performance of the index, compounded daily, less a Daily Investor Fee, the Daily Financing Charge and, if applicable, the Redemption Fee Amount. The index is an equal-dollar weighted index designed to represent the 10 U.S. listed stocks with the largest market capitalization in the energy/oil sector.

Microsectors Us Big Oil Index 3X Leveraged Etn

Bank Of Montreal MicroSectors U.S. Big Oil 3 Leveraged ETNs due February 17, 2045

MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.14) by 57.14 percent. This is unchanged from the same period last year.

Earnings

Earnings Beats

News

MNOV

MediciNova Q1 EPS $(0.06) Beats $(0.14) Estimate

Citigroup analyst Steven Enders maintains Appian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPN#NASDAQ">APPN</a>) with a Buy and raises the price target from $40 to $41.

Price Target

Analyst Ratings

APPN

Citigroup Maintains Buy on Appian, Raises Price Target to $41

JP Morgan analyst Ranjan Sharma upgrades Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) from Neutral to Overweight and raises the price target from $135 to $190.

Upgrades

JP Morgan Upgrades Sea to Overweight, Raises Price Target to $190

The Consumer Price Index (CPI) was 2.3% higher than a year ago, the Bureau of Labor Statistics said Tuesday, below the economists&#8217; expectations of 2.4% <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/05/45374267/inflation-eases-in-april-as-trumps-tariffs-dont-push-prices-higher" rel="noreferrer noopener">and the previous reading</a>.
The monthly gain was 0.2%, rebounding from a prior decline of 0.1%, yet <a target="_blank" href="https://www.benzinga.com/topic/cpi" rel="noreferrer noopener">falling short of a 0.3% forecast</a>.
The core CPI rose to 2.8% on an annual basis, unchanged from both the previous and expected 2.8%.
Month over month, it increased 0.2%, inching higher from the 0.1% uptick in March but below expectations of 0.3%.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44772840/analysts-warn-of-choppy-tech-outlook-despite-inflation-relief" rel="noreferrer noopener">Inflation Might Be Easing But Tech Outlook Still Choppy, Analysts Warn</a>
Shelter remained a major contributor to inflation, rising 0.3% in April and accounting for over half of the monthly increase in the overall Consumer Price Index. Meanwhile, several categories posted price declines, including airline fares, used cars and trucks, communication services, and apparel.
JP Morgan writes, &#8220;Despite an overall cooler-than-expected report, the April CPI likely shows modest tariff pass-through with several hardlines retailers taking price ahead of costs.&#8221;
On a quarterly basis, the most significant price drops compared to the fourth quarter were seen in TVs, sporting goods, auto parts (which moved from rising to falling prices), and motor oil/coolant/fluids (where prices are still rising but at a slower rate).
Meanwhile, prices went up or dropped less sharply in categories like building products, which shifted to rising prices, toys/games/hobbies/playground equipment, helped by price increases noted by companies like Hasbro Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) and Mattel Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>), pet food (smaller price declines), and home furnishings (prices increased).
Inflation for food at home dropped by 0.4 percentage points from last month, now sitting just above 2% year-over-year.
Grocery prices rose by about 0.4 percentage points during the recent retail quarter, and analyst Christopher Horvers expects more price increases in the second quarter.
Pet food prices increased slightly, rising 0.3 percentage points from the previous month, though they&#8217;re still down 0.6% compared to last year.
Looking at two-year trends, food-at-home inflation dipped about 0.2 percentage points, while pet food prices fell by roughly 0.8 percentage points.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance" target="_blank" rel="noreferrer noopener">UnitedHealth Names New CEO, Suspends 2025 Guidance, Stock Plunges</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Government

Macro Economic Events

Econ #s

Economics

Markets

General

CPI Undershoots But Core Inflation Stays Stubborn: JP Morgan

JP Morgan analyst Kenneth Worthington maintains P10 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PX#NYSE">PX</a>) with a Overweight and lowers the price target from $15 to $14.5.

JP Morgan Maintains Overweight on P10, Lowers Price Target to $14.5

Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) reported quarterly earnings of $2.56 per share which beat the analyst consensus estimate of $2.29 by 11.79 percent. This is a 25700 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $211.79 million which beat the analyst consensus estimate of $117.69 million by 79.95 percent. This is a 213.98 percent increase over sales of $67.45 million the same period last year.

NUTX

Nutex Health Q1 EPS $2.56 Beats $2.29 Estimate, Sales $211.79M Beat $117.69M Estimate

Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) has outperformed the market over the past 15 years by 4.73% on an annualized basis producing an average annual return of 16.42%. Currently, Autodesk has a market capitalization of $63.26 billion. 
Buying $100 In ADSK: If an investor had bought $100 of ADSK stock 15 years ago, it would be worth $985.11 today based on a price of $297.01 for ADSK at the time of writing.
<h3>Autodesk's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747172715_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ADSK

Here's How Much $100 Invested In Autodesk 15 Years Ago Would Be Worth Today

Gamehost (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GH#TSX">GH</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.24 by 8.33 percent. This is a 18.18 percent increase over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $21.22 million which beat the analyst consensus estimate of $20.50 million by 3.52 percent. This is a 3.15 percent increase over sales of $20.57 million the same period last year.

TSX:GH

Gamehost Q1 GAAP EPS $0.26 Beats $0.24 Estimate, Sales $21.22M Beat $20.50M Estimate

JP Morgan analyst Brian Cheng downgrades ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) from Overweight to Neutral and lowers the price target from $15 to $8.

Downgrades

ITOS

JP Morgan Downgrades ITeos Therapeutics to Neutral, Lowers Price Target to $8

Offerings

ZONE

CleanCore Solutions Inc: Files For Mixed Shelf Offering Up To $150M

Jones Trading analyst Catherine Novack maintains Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) with a Buy and lowers the price target from $10 to $6.

FEMY

Jones Trading Maintains Buy on Femasys, Lowers Price Target to $6

Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/05/b45393289/nu-holdings-ltd-reports-first-quarter-2025-financial-results"> from the report.&nbsp;</a>
The Details:&nbsp;Nu Holdings&nbsp;reported earnings of 12 cents per share, which missed the consensus estimate of 13 cents. Quarterly revenue came in at $3.2 billion, which missed the Street estimate of $3.23 billion.
Read Next: <a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time?utm_source=articleShare">Trump Again Promises Lower Drug Prices By &#8216;Cutting Out Middlemen&#8217; Like UnitedHealth, CVS: Will It Work This Time?</a>
For the first quarter, Nu Holdings reported: 
<ul class="wp-block-list">
<li>4.3 million customers added in the first quarter, driving a 19% year-over-year increase of 19.3 million, reaching a total of 118.6 million customers globally by March 31, 2025.</li>
<li>Monthly Average Revenue per Active Customer (ARPAC) grew 5% sequentially and 17% year-over-year on an FX-neutral basis to $11.2 in Q1. </li>
<li>Monthly Average Cost to Serve Per Active Customer remained below the dollar level, at seven cents per customer, a 4% year-over-year reduction and a decline of 12% sequentially.</li>
<li>Net interest income increased 34% year-over-year and 5% sequentially, reaching a new all-time high of $1.8 billion.</li>
</ul>
&#8220;Starting 2025 strong, Nubank reached 118.6 million customers, adding over four million in a single quarter, showcasing its powerful platform scalability across Brazil, Mexico and Colombia. This growth is driven by deepening customer engagement: 98.7 million monthly active users and an activity rate exceeding 83%. Revenues surged 40% year-over-year (FXN) to $3.2 billion, driven by a 62% expansion in the interest-earning portfolio,&#8221; said David Vélez, CEO of Nubank.
Warren Buffett holds shares of Nu Holdings in Berkshire Hathaway, <a href="https://www.benzinga.com/markets/cryptocurrency/22/05/27208096/warren-buffett-now-owns-bitcoin-heres-how-the-oracle-of-omaha-got-exposure-3" target="_blank" rel="noreferrer noopener">giving him exposure </a>to the company.
NU Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Nu Holdings stock was down 5.71% at $12.39&nbsp;after-hours on Tuesday.&nbsp;&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45353123/quantum-stocks-are-hot-in-2025-biggest-movers-to-watch?utm_source=articleShare">Quantum Stocks Are Hot In 2025: Biggest Movers To Watch&nbsp;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

After-Hours Center

Movers

Buffett-Backed Nu Holdings Stock Drops After Worse-Than-Expected Q1 Results: Details

Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) on Tuesday released statistically significant final overall survival (OS) results from the phase III APHINITY study in people with human epidermal growth factor receptor 2 (HER2)-positive <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">early-stage breast cancer</a>.
After ten years, the risk of death was reduced by 17% for people treated with Perjeta (pertuzumab), Herceptin (trastuzumab), and chemotherapy (the Perjeta-based regimen) for a year as post-surgery (adjuvant) treatment, compared with individuals who received Herceptin, chemotherapy, and placebo.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/04/44934942/roche-plans-50-billion-us-investment-over-5-years-with-12000-new-jobs" target="_blank" rel="noreferrer noopener">Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs</a>
After ten years, <a target="_blank" href="https://www.roche.com/media/releases/med-cor-2025-05-13" rel="noreferrer noopener">results</a> show:
<ul class="wp-block-list">
<li>91.6% of people treated with the Perjeta-based regimen were alive at ten years versus 89.8% of those treated with Herceptin, chemotherapy, and placebo (hazard ratio [HR]=0.83, p-value=0.044).</li>
<li>A 21% reduction in the risk of death was seen in the prespecified subgroup of people with lymph node-positive disease (HR=0.79).</li>
<li>The previously reported invasive disease-free survival (primary endpoint) benefit was maintained (HR=0.79), strengthening results from earlier APHINITY analyses. No benefit was seen in the node-negative subgroup.</li>
<li>The safety profile, including cardiac safety, was consistent with previous studies, and no new or unexpected safety signals were identified.</li>
</ul>
Full results will be presented at the 2025 European Society for Medical Oncology Breast Cancer Congress.
In April, Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) and&nbsp;Roche temporarily&nbsp;halted&nbsp;several clinical studies for Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with <a target="_blank" href="https://www.benzinga.com/25/04/44634689/sareptaroche-suspend-elevidys-gene-therapy-trials-in-europe-after-patient-death" rel="noreferrer noopener">Duchenne muscular dystrophy</a>.
The company reported a patient death following treatment with Elevidys, having suffered&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44376919/sarepta-therapeutics-reports-patient-death-post-elevidys-gene-therapy-treatment-stock-plunges" rel="noreferrer noopener">acute liver failure</a>.
In April, Roche&#8217;s MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) intravenous infusion for relapsing multiple sclerosis did not meet its primary endpoint in showing additional benefit in slowing disability progression compared with the currently approved <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44613949/why-is-pharma-giant-roche-stock-trading-lower-on-wednesday" rel="noreferrer noopener">Ocrevus IV 600 mg dose</a>.
Price Action: RHHBY stock is trading at $38.34 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45383468/earnings-just-put-dan-loebs-bets-to-the-testheres-what-held-up" target="_blank" rel="noreferrer noopener">Earnings Just Put Dan Loeb&#8217;s Bets To The Test — Here&#8217;s What Held Up</a></li>
</ul>
Photo by OleksSH via Shutterstock

Biotech

Large Cap

Health Care

RHHBY

SRPT

Ten-Year Data From Roche's Breast Cancer Trial Shows Perjeta-Based Regimen Cuts Death Risk By 17%

In today's privacy-led economy, where global regulations are tightening and user expectations are shifting, consent isn't optional, it's strategic. The way your business handles consent can either build trust or quietly erode it.
Usercentrics <a href="http://usercentrics.sjv.io/3JRRWA">Cookiebot CMP</a> doesn't just help you comply with privacy laws. It helps you stay visible in a digital world where data fuels everything from analytics to ad performance. And in an age where Google Consent Mode is mandatory for EU-based tracking, that visibility can make or break your marketing ROI.
<h2 class="wp-block-heading">Privacy Is the New Baseline</h2>
If your website drops cookies or uses online tracking (and 99.9% of them do), you're expected to obtain clear, informed consent from your users. That's not just a GDPR thing. It's also baked into the <a href="https://oag.ca.gov/privacy/ccpa">California Consumer Privacy Act</a> (CCPA/CPRA), <a href="https://iapp.org/resources/article/brazilian-data-protection-law-lgpd-english-translation/">Brazil's LGPD</a>, <a href="https://popia.co.za/">South Africa's POPIA</a>, and the <a href="https://commission.europa.eu/strategy-and-policy/priorities-2019-2024/europe-fit-digital-age/digital-markets-act-ensuring-fair-and-open-digital-markets_en">EU's Digital Markets Act</a> (DMA).
These aren't soft guidelines. They're enforceable laws, and regulators have proven they're willing to act. On top of that, <a href="https://support.google.com/tagmanager/answer/13695607?hl=en">Google's move to enforce Consent Mode for ads and analytics in the EU/EEA that started in March 2024</a> only raises the stakes. If your business relies on data, you'll want to make sure your cookie consent solution is up to par.
<h2 class="wp-block-heading">What Makes Cookiebot CMP Worth It?</h2>
There's a difference between adding a random cookie banner to your homepage and using a Consent Management Platform (CMP) that's designed to scale. Cookiebot CMP isn't just a compliance Band-Aid. It's a <a href="http://usercentrics.sjv.io/3JRRWA">fully integrated system</a> built to scan your site, detect every cookie and tracker, categorize them correctly, and handle user consent in a way that meets both legal and usability standards.
It's used on over 2.3 million websites and apps. It supports over 47 languages and handles more than 7 billion user consents per month. These aren't vanity numbers, they're evidence that Cookiebot CMP is doing the hard work behind the scenes so your business doesn't fall out of step with evolving regulations.
<h2 class="wp-block-heading">Google-Ready by Design</h2>
Google doesn't hand out certifications lightly, but Cookiebot CMP is a Gold Tier certified CMP partner for Google Consent Mode. That means your consent data integrates with Google Ads and Google Analytics. Even if a user denies consent, Google's machine learning models can still generate conversion insights based on modeled data. You don't just avoid penalties, you preserve your performance.
Cookiebot CMP works natively with Google Tag Manager and supports the <a href="https://iabeurope.eu/transparency-consent-framework/">Transparency and Consent Framework (TCF) 2.2</a>, which is a key requirement for any site running programmatic ads in Europe. Bottom line? You don't have to cobble together workarounds to keep your tracking operational and compliant.
<h2 class="wp-block-heading">Built for Real Businesses, Not Just Legal Teams</h2>
One of the common pain points with compliance software is that it's often built either for lawyers or for developers, rarely both. Cookiebot CMP manages to meet in the middle. The interface is intuitive enough for marketers and content managers, but flexible enough for developers who need more control.
It automatically scans your site, detects new cookies as they're added, and keeps your consent banner updated accordingly. You can deploy it with or without a CMS, and it's compatible with various tech stacks. If you want to match your consent banner to your brand, you've got full design control using HTML, CSS, or JavaScript.
And yes, it works across devices, regions, and languages so your visitors in Paris, São Paulo, and San Francisco can each see a localized, legally correct version of your banner. That kind of flexibility isn't just nice to have. It's <a href="http://usercentrics.sjv.io/3JRRWA">a necessity when you're operating in multiple jurisdictions</a> or planning to scale.
<h2 class="wp-block-heading">Your Consent Banner, Your Brand</h2>
Cookiebot CMP gets that user experience matters. A jarring or generic consent banner can send the wrong signal especially when the rest of your site is polished and professional. That's why the platform allows you to fully customize the banner's layout, messaging, and design to reflect your brand.
You can use pre-built templates to get started quickly or go fully custom with your own code. Either way, your cookie consent banner doesn't have to feel like a legal disclaimer slapped on top of a thoughtful brand experience. It can be cohesive, localized, and most importantly transparent.
<h2 class="wp-block-heading">Legal Peace of Mind, Baked In</h2>
Cookiebot CMP comes built with compliance standards for laws like GDPR, the ePrivacy Directive, CCPA/CPRA, LGPD, and POPIA. It also supports the latest version of Google Consent Mode by default. That means less time interpreting legal updates and more time focusing on your business.
With integrations into common ad tech and analytics platforms, including IAB TCF 2.2 and Google's ecosystem, you don't need to worry about whether you're covered. The platform is built to adapt as regulations evolve so you&#8217;re not constantly playing catch-up with each new data law.
<h2 class="wp-block-heading">Easy to Start, Scalable as You Grow</h2>
Cookiebot CMP offers a <a href="http://usercentrics.sjv.io/3JRRWA">14-day free trial</a> so you can see how it works before committing. If your website has fewer than 1000 sessions per month, you can continue using it for free. Once your business expands, plans start at just $8 per month.
You can upgrade at any time, no hidden upsell tricks and you gain access to premium features like multilingual auto-translation, monthly consent reports, full banner customization, and priority support. Whether you're managing one site or twenty, the pricing structure supports your growth instead of penalizing it.
<h2 class="wp-block-heading">Trusted by Global Brands</h2>
This isn't a fly-by-night product cobbled together in a startup garage. Cookiebot CMP is used by global names like Canon, Bauhaus, Pepco, and Orbico: businesses that depend on trust, reputation, and high-performance marketing. That kind of client list says a lot about the platform's reliability, but more importantly, about its adaptability across sectors.
If you're running a B2C e-commerce brand, managing a large corporate website, or simply want peace of mind that your consent data is handled properly, it's worth considering the same CMP these brands rely on.
<h2 class="wp-block-heading">Consent Isn't a Burden, It's a Brand Statement</h2>
Here's the thing most businesses miss: consent isn't just about compliance. It's about showing your users that you respect their data. That you're transparent. That you're worthy of trust. And trust, once earned, pays dividends like longer sessions, higher conversions, better retention.
The real risk isn't overcomplying. It's underestimating how quickly noncompliance can damage your data quality, your ad performance, and your brand. Usercentrics Cookiebot CMP <a href="http://usercentrics.sjv.io/3JRRWA">helps you eliminate that risk</a>, without making it your full-time job.

Tech

Why Usercentrics Cookiebot CMP Is a Must-Have for Privacy-Led Businesses

DA Davidson analyst Rudy Kessinger maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and raises the price target from $415 to $435.

CYBR

DA Davidson Maintains Buy on CyberArk Software, Raises Price Target to $435

K-Bro Linen (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KBL#TSX">KBL</a>) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate of $0.28 by 14.29 percent. This is a 5.88 percent decrease over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $90.97 million which beat the analyst consensus estimate of $89.18 million by 2.01 percent. This is a 13.39 percent increase over sales of $80.23 million the same period last year.

TSX:KBL

K-Bro Linen Q1 Adj. EPS $0.32 Beats $0.28 Estimate, Sales $90.97M Beat $89.18M Estimate

PARR

Par Pacific Holdings Files For Mixed Shelf Offering; Size Not Disclosed

CIBC analyst Cosmos Chiu maintains Pan American Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NYSE">PAAS</a>) with a Outperformer and lowers the price target from $42 to $39.

PAAS

CIBC Maintains Outperformer on Pan American Silver, Lowers Price Target to $39

CSCI

Cosciens Biopharma Q1 EPS $(1.16) Up From $(4.74) YoY, Sales $1.50M Up From $4.00K YoY

Republic Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) has outperformed the market over the past 15 years by 3.27% on an annualized basis producing an average annual return of 14.96%. Currently, Republic Services has a market capitalization of $74.37 billion. 
Buying $100 In RSG: If an investor had bought $100 of RSG stock 15 years ago, it would be worth $799.97 today based on a price of $237.99 for RSG at the time of writing.
<h3>Republic Services's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747171824_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Bank Of Montreal MicroSectors U.S. Big Oil 3 Leveraged ETNs due February 17, 2045

Notizie

Ultime notizie per Bank Of Montreal MicroSectors U.S. Big Oil 3 Leveraged ETNs due February 17, 2045 (ARCA:NRGU)

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO